Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

バスルファンの後の放射線感受性.

G Vassal, O Hartmann, J L Habrand

    Lancet (London, England)
    |March 7, 1987
    PubMed
    まとめ

    No abstract available in PubMed .

    関連する実験動画

    関連する概念動画

    こちらも読む

    関連記事

    共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

    並び替え
    Same author

    Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program.

    European journal of cancer (Oxford, England : 1990)·2024
    Same author

    An academia-driven compassionate use program for patients with recurrent H3K27-altered diffuse midline glioma: a new way to access innovation when clinical trials are lacking.

    Annals of oncology : official journal of the European Society for Medical Oncology·2023
    Same author

    Access to essential anticancer medicines for children and adolescents in Europe.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same author

    Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.

    AJNR. American journal of neuroradiology·2019
    Same author

    [Re-irradiation of head and neck cancers: Target volumes, technical evolutions and prospects].

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2018
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    Same journal

    Dual mobility total hip replacement in fractures: stability promotes patient confidence.

    Lancet (London, England)·2026
    Same journal

    Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

    Lancet (London, England)·2026
    関連記事をすべて見る